Valeant Pharmaceuticals International and GlaxoSmithKline have received FDA approval for Potiga (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.      “We are so pleased to reach such an important milestone with the U.S. approval of Potiga by the FDA,” said Susan Hall, Ph.D., head of R&D at Valeant. ”We believe this product will play a needed role in the management of partial onset seizures in appropriate p...